CVS Health selected to administer recently authorized COVID-19 therapy
To help respond to the surge of COVID-19 cases in the U.S., CVS Health was selected by the U.S. Department of Health and Human Services, to help pilot the administration of bamlanivimab, a monoclonal antibody therapy, to eligible COVID-19 patients at-risk of severe infection or complications resulting from the virus. Under this pilot and pursuant to an emergency use authorization (EUA), Coram, the infusion care business of CVS Health, will administer the intravenous therapy in patients’ homes or long-term care facilities to help meet the growing demand for these new treatments.
This solution, part of Operation Warp Speed, is one more way that Coram is working to help keep patients out of inpatient and hospital settings to help mitigate the pressures on the health care system to preserve important hospital resources for the most critical patients. Since early in the COVID-19 pandemic, Coram has partnered with hospitals to safely transition eligible infusion patients home to help ensure hospital bed capacity to treat COVID-19 patients.